TD Asset Management Inc Sells 51,890 Shares of Vera Therapeutics, Inc. $VERA

TD Asset Management Inc decreased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 20.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 200,274 shares of the company’s stock after selling 51,890 shares during the period. TD Asset Management Inc’s holdings in Vera Therapeutics were worth $4,718,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quarry LP increased its stake in shares of Vera Therapeutics by 25.0% during the first quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after purchasing an additional 500 shares in the last quarter. AlphaQuest LLC increased its stake in shares of Vera Therapeutics by 404.7% during the first quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock valued at $96,000 after purchasing an additional 3,213 shares in the last quarter. Fifth Third Bancorp bought a new position in shares of Vera Therapeutics during the second quarter valued at approximately $102,000. GAMMA Investing LLC increased its stake in shares of Vera Therapeutics by 1,779.1% during the first quarter. GAMMA Investing LLC now owns 8,287 shares of the company’s stock valued at $199,000 after purchasing an additional 7,846 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Vera Therapeutics by 19.7% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,533 shares of the company’s stock valued at $229,000 after purchasing an additional 1,572 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on VERA. Bank of America began coverage on shares of Vera Therapeutics in a research note on Thursday, October 16th. They set a “buy” rating and a $48.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a research report on Thursday, September 18th. Wolfe Research reissued a “peer perform” rating on shares of Vera Therapeutics in a research report on Monday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Vera Therapeutics from $56.00 to $53.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.50.

Vera Therapeutics Trading Down 3.3%

Shares of Vera Therapeutics stock opened at $30.20 on Tuesday. The company’s fifty day simple moving average is $25.68 and its 200-day simple moving average is $23.48. The stock has a market capitalization of $1.93 billion, a PE ratio of -8.44 and a beta of 1.23. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.61. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same period last year, the firm posted ($0.62) EPS. As a group, equities analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.